文献速递膀胱癌与上尿路尿路上皮癌

丝裂霉素C在中危非肌层浸润性膀胱癌中的作用:系统综述与Meta分析

The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
PubMed 文献 · Eur Urol Oncol · 2024-06-19

该系统综述与Meta分析检索了PubMed、Scopus和Web of Science截至2023年11月的研究,评估辅助性膀胱内丝裂霉素C(MMC)预防中危非肌层浸润性膀胱癌复发的效果,并比较不同MMC方案。共14项研究纳入系统综述,11项纳入无复发生存(RFS)Meta分析。结果显示MMC诱导加维持方案的短期RFS率与卡介苗(BCG)维持方案相当;40 mg MMC在预防复发方面似乎比30 mg更有效;未观察到更长维持方案带来RFS获益。

要点

  • MMC诱导加维持方案的短期RFS率与BCG维持方案相当。
  • 40 mg MMC在预防复发方面似乎比30 mg更有效。
  • 未观察到更长维持方案带来RFS获益。

核心结论

  • MMC诱导加维持方案在中危非肌层浸润性膀胱癌中似乎提供与BCG维持方案等效的短期RFS率。
  • 作为辅助诱导和维持治疗,40 mg MMC在预防复发方面似乎比30 mg更有效。
  • 未观察到更长维持方案带来RFS获益。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Scopus和Web of Science截至2023年11月的研究。
  • 纳入接受辅助MMC的中危非肌层浸润性膀胱癌患者中调查RFS的研究;前瞻性试验比较不同MMC方案或其他膀胱内药物者符合纳入条件。
  • 共14项研究纳入系统综述,11项纳入RFS Meta分析。

主要发现

  • MMC诱导加维持治疗患者的1年、2年和5年RFS率分别为84%(95%CI 79-89%)、75%(95%CI 68-82%)和51%(95%CI 40-63%)。
  • BCG维持治疗患者的1年、2年和5年RFS率分别为88%(95%CI 83-94%)、78%(95%CI 67-89%)和66%(95%CI 57-75%)。
  • MMC维持方案的2年RFS率:40 mg MMC(2项研究)为76%(95%CI 69-84%),30 mg MMC(4项研究)为66%(95%CI 60-72%)。
  • BCG维持提供的2年RFS与40 mg MMC加维持相当(78% vs 76%)。
  • RFS未因MMC维持持续时间(>1年 vs 1年 vs <1年)而不同。

临床怎么用

  • 作者认为,对于中危非肌层浸润性膀胱癌,MMC诱导加维持方案似乎提供与BCG维持方案等效的短期RFS率。
  • 作者认为,作为辅助诱导和维持治疗,40 mg MMC在预防复发方面似乎比30 mg更有效。
  • 作者指出,需要进一步试验以获取关于最佳MMC剂量和治疗时间的更强证据。

局限性

  • 需要进一步试验以获取关于最佳MMC剂量和治疗时间的更强证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Intravesical mitomycin C (MMC) instillations are recommended to prevent recurrence of intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC); however, the optimal regimen and dose are uncertain. Our aim was to assess the effectiveness of adjuvant MMC and compare different MMC regimens in preventing recurrence. METHODS: We performed a comprehensive search in PubMed, Scopus, and Web of Science in November 2023 for studies investigating recurrence-free survival (RFS) among patients with IR-NMIBC who received adjuvant MMC. Prospective trials with different MMC regimens or other intravesical drugs as comparators were considered eligible. KEY FINDINGS AND LIMITATIONS: Overall, 14 studies were eligible for systematic review and 11 for meta-analysis of RFS. Estimates of 1-yr, 2-yr, and 5-yr RFS rates were 84% (95% confidence interval [CI] 79-89%), 75% (95% CI 68-82%), and 51% (95% CI 40-63%) for patients treated with MMC induction plus maintenance, and 88% (95% CI 83-94%), 78% (95% CI 67-89%), and 66% (95% CI 57-75%) for patients treated with bacillus Calmette-Guérin (BCG) maintenance, respectively. Estimates of 2-yr RFS rates for MMC maintenance regimens were 76% (95% CI 69-84%) for 40 mg MMC (2 studies) and 66% (95% CI 60-72%) for 30 mg MMC (4 studies). Among the studies included, BCG maintenance provided comparable 2-yr RFS to 40 mg MMC with maintenance (78% vs 76%). RFS did not differ by MMC maintenance duration (>1 yr vs 1 yr vs <1 yr). CONCLUSIONS AND CLINICAL IMPLICATIONS: MMC induction and maintenance regimens seem to provide short-term RFS rates equivalent to those for BCG maintenance in IR-NMIBC. For adjuvant induction and maintenance, 40 mg of MMC appears to be more effective in preventing recurrence than 30 mg. We did not observe an RFS benefit for longer maintenance regimens. PATIENT SUMMARY: For patients with intermediate-risk non-muscle-invasive bladder cancer, bladder treatments with a solution of a drug called mitomycin C (MMC) seem to be as effective as BCG (bacillus Calmette-Guérin) in preventing recurrence after tumor removal. Further trials are needed for stronger evidence on the best MMC dose and treatment time.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Scilipoti P, Ślusarczyk A, de Angelis M, et al. The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2024. PMID: 38902138. doi:10.1016/j.euo.2024.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。